Immuneering (IMRX)
NASDAQ:IMRX
Top Page
Immuneering
(NASDAQ:IMRX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▲(0.00% Upside)
Action:ReiteratedDate:04/06/26
The score is primarily held back by weak financial performance (minimal revenue, sustained losses, and significant cash burn), partly offset by low leverage. Technical indicators are moderately constructive, and a positive clinical-data corporate event provides upside optionality, but valuation remains constrained by ongoing unprofitability and no dividend support.
Positive Factors
Low leverage
Very low leverage provides durable financial flexibility for a cash-burning biotech. With minimal debt service the company can prioritize R&D and trials, reduce default risk, and preserve optionality for partnerships or milestone-based financing over the coming months.
Negative Factors
Sustained cash burn
Persistent large negative free cash flow reflects heavy R&D and operating spend and implies ongoing external financing needs. Over the medium term this constrains strategic flexibility, raises dilution risk, and can slow development timelines if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage provides durable financial flexibility for a cash-burning biotech. With minimal debt service the company can prioritize R&D and trials, reduce default risk, and preserve optionality for partnerships or milestone-based financing over the coming months.
Read all positive factors
Immuneering (IMRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$365.94M
Dividend YieldN/A
Average Volume (3M)979.91K
Price to Earnings (P/E)―
Beta (1Y)1.87
Revenue GrowthN/A
EPS Growth9.32%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding64,652,920
10 Day Avg. Volume530,364
30 Day Avg. Volume979,915
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.00
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
$17.00Price Target Upside209.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Immuneering Business Overview & Revenue Model
Company Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, c...
How the Company Makes Money
null...
Immuneering Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.Positive Updates
Extraordinary Overall Survival in Pancreatic Cancer
In September, Immuneering Corporation announced 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine nab-paclitaxel, compared to approximately 47% with the standard of care.
Negative Updates
Challenges with FOLFIRINOX Combination
While demonstrating potential, the FOLFIRINOX combination is not currently prioritized due to harsher side effects, limiting its use to younger, higher fitness patients.
Read all updates
Q3-2025 Updates
Positive
Negative
Extraordinary Overall Survival in Pancreatic Cancer
In September, Immuneering Corporation announced 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine nab-paclitaxel, compared to approximately 47% with the standard of care.
Read all positive updates
Company Guidance
During the Immuneering Corporation's third-quarter 2025 conference call, CEO Benjamin Zeskind highlighted notable guidance for the company's development plans, focusing on their Phase IIa trial of atebimetinib. Immuneering plans to prioritize atebimetinib in combination with gemcitabine nab-paclitaxel due to its impressive 86% overall survival rate at nine months in first-line pancreatic cancer patients, compared to the standard 47%. The company aims to present updated results at a major medical meeting in 2026. Financially, Immuneering strengthened its position with $225 million in cumulative financing, extending its cash runway into 2029, which supports the planned pivotal Phase III trials and other developments. Additionally, the company is preparing to dose the first patient in a pivotal trial in mid-2026 and has planned studies with Regeneron and Eli Lilly, indicating broad potential for atebimetinib across various cancer types.Immuneering Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 316.95K | 2.08M |
| Gross Profit | -698.89K | 0.00 | 0.00 | 158.83K | 926.89K |
| EBITDA | -58.68M | -63.69M | -58.06M | -51.47M | -33.73M |
| Net Income | -56.02M | -61.04M | -53.47M | -50.51M | -33.54M |
Balance Sheet | |||||
| Total Assets | 231.99M | 52.71M | 102.58M | 122.37M | 166.70M |
| Cash, Cash Equivalents and Short-Term Investments | 172.83M | 36.14M | 85.67M | 105.52M | 149.20M |
| Total Debt | 3.82M | 4.16M | 4.46M | 4.84M | 5.36M |
| Total Liabilities | 13.50M | 11.33M | 12.01M | 12.52M | 10.72M |
| Stockholders Equity | 218.48M | 41.39M | 90.58M | 109.85M | 155.98M |
Cash Flow | |||||
| Free Cash Flow | -45.49M | -55.08M | -49.31M | -44.84M | -30.91M |
| Operating Cash Flow | -45.34M | -55.00M | -48.97M | -44.10M | -30.85M |
| Investing Cash Flow | -88.74M | 26.43M | 7.30M | 41.83M | -75.62M |
| Financing Cash Flow | 226.58M | 5.30M | 28.44M | 19.00K | 144.26M |
Immuneering Technical Analysis
Positive
5.50
Price Trends
5.10
Positive
5.63
Positive
5.52
Positive
Market Momentum
0.09
Negative
60.49
Neutral
78.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Positive. The current price of 5.5 is above the 20-day moving average (MA) of 5.17, above the 50-day MA of 5.10, and below the 200-day MA of 5.52, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 60.49 is Neutral, neither overbought nor oversold. The STOCH value of 78.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRX.
Immuneering Risk Analysis
Immuneering disclosed 90 risk factors in its most recent earnings report. Immuneering reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immuneering Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $503.02M | -8.10 | -48.65% | ― | 332.71% | 75.73% | |
52 Neutral | $365.94M | -5.17 | -43.33% | ― | ― | 9.32% | |
52 Neutral | $528.76M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $390.85M | -2.29 | -65.76% | ― | ― | 18.39% | |
48 Neutral | $434.94M | -3.10 | -71.25% | ― | ― | -11.41% |
* Healthcare Sector Average
IMRX
Immuneering
5.66
4.42
356.45%
LRMR
Larimar Therapeutics
5.09
3.31
185.96%
RCKT
Rocket Pharmaceuticals
3.60
-1.34
-27.13%
IVVD
Invivyd
1.78
1.28
256.00%
AURA
Aura Biosciences Inc
6.78
1.81
36.42%
Immuneering Corporate Events
Business Operations and StrategyProduct-Related Announcements
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
Positive
Jan 7, 2026
On January 7, 2026, Immuneering announced updated interim results from its ongoing Phase 2a trial of atebimetinib, a once-daily oral MEK inhibitor, combined with modified Gemcitabine/nab-Paclitaxel in first-line pancreatic cancer patients, showing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.